Savara Inc. completed an underwritten public offering of 28,452,381 shares of common stock at $4.20 per share, including 4,642,857 shares sold under the underwriters’ option to purchase additional shares.
The company also sold 7,142,857 pre‑funded warrants to purchase common stock at $4.199 per warrant, in lieu of common stock to certain investors.
The offering raised $149.5 million in gross proceeds, the largest public offering the company has completed to date.
Proceeds will be used to support the clinical development of MOLBREEVI, the company’s lead product for autoimmune pulmonary alveolar proteinosis, and to fund regulatory approval efforts and early commercialization activities.
Savara’s cash position as of December 31 2024 was $196.3 million, with a debt‑to‑equity ratio of 0.25. The company has previously completed a $130 million offering in October 2025 and a $100 million offering in June 2024.
The offering was managed by a syndicate of investment banks including Jefferies, Piper Sandler, Guggenheim Securities, Oppenheimer & Co., Citizens Capital Markets, and H.C. Wainwright & Co., and was filed under an existing shelf registration statement with the SEC in May 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.